


Etavopivat

Cat. No.:	HY-139573		
CAS No.:	2245053-57-8		
Molecular Formula:	C ₂₂ H ₂₃ N ₃ O ₆ S		
Molecular Weight:	457.5		
Target:	Pyruvate Kinase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (109.29 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1858 mL	10.9290 mL	21.8579 mL
	5 mM		0.4372 mL	2.1858 mL	4.3716 mL
	10 mM		0.2186 mL	1.0929 mL	2.1858 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Etavopivat is a potent, selective, and orally active erythrocyte pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects that can be used in studies of sickle cell disease and other haemoglobinopathies^{[1][2]}.

In Vitro

Etavopivat (20 μM, 4 h) improves haemoglobin-oxygen affinity and reduces the sickle point (PoS) in human red blood cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Etavopivat (500-1000 mg/kg, p.o., daily, 2 weeks) improves RBC survival and Hb levels in SCA mice^[1].
 Etavopivat (3-22 mg/kg, p.o., daily, 5 days) causes an increase in 2,3-DPG and ATP in crab-eating monkeys at doses of 8 mg/kg and 22 mg/kg^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCA mice ^[1]
Dosage:	500-1000 mg/kg

Administration:	p.o., daily, 2 weeks
Result:	Decreased the levels of 2,3-DPG. Increased ATP levels. Reduced sickling in vivo.

REFERENCES

- [1]. Schroeder P, et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219.
- [2]. Shrestha A, et al. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Blood Adv. 2021 May 11;5(9):2385-2390.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA